A new way of using umbilical cord blood for treating blood diseases could make the treatment more accessible to patients who need a stem cell transplant. A Phase II clinical trial of patients undergoing a cord blood transplant plus a stem cell product derived from pooled cord blood units showed that 27 of 28 patients (96%) with leukemias and GVHD survived at least one year and none of the patients experienced severe acute or chronic graft-versus-host disease, which are common complications of stem cell transplantation.
The results have been published in the Journal of Clinical Oncology.
“This is the first time transplant patients received cells from what amounts to nine different human beings,” said the study’s principal investigator, Filippo Milano, MD, Ph.D...
Read More
Recent Comments